2023
Nonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19
Cohen A, Glick L, Lee S, Kunitomo Y, Tsang D, Pitafi S, Toro P, Ristic N, Zhang E, Carey G, Datta R, Dela Cruz C, Gautam S. Nonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19. European Clinical Respiratory Journal 2023, 10: 2174640. PMID: 36815942, PMCID: PMC9930745, DOI: 10.1080/20018525.2023.2174640.Peer-Reviewed Original ResearchSevere COVID-19Bacterial superinfectionBacterial pneumoniaCOVID-19Lower respiratory culturesSuperimposed bacterial pneumoniaUtility of procalcitoninProcalcitonin measurementImmune biomarkersClinical resemblanceRespiratory culturesImmunomodulatory agentsProcalcitoninPatientsBacterial infectionsSuperinfectionCurve analysisSignificant riskCharacteristic curvePneumoniaTime of cultureDiagnosisInfectionBiomarkers
2022
Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
Tuan J, Kayani J, Fisher A, Kotansky B, Dembry L, Datta R. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e83. PMID: 36483361, PMCID: PMC9726471, DOI: 10.1017/ash.2022.229.Peer-Reviewed Original ResearchDalbavancin administrationOutpatient parenteral antimicrobial therapyDose of dalbavancinMedian antibiotic durationSoft tissue infectionsParenteral antimicrobial therapyAntibiotic durationDeveloped hepatotoxicityClinical cureSeptic arthritisClinical outcomesAntimicrobial therapyPatientsAdministrationDaysEndocarditisArthritisBacteremiaOsteomyelitisHepatotoxicityTherapyDalbavancinInfectionDose
2021
Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness
Datta R, Barrett A, Burk M, Salone C, Au A, Cunningham F, Fisher A, Dembry LM, Akgün KM. Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness. Infection Control And Hospital Epidemiology 2021, 43: 1488-1491. PMID: 33985598, PMCID: PMC8160489, DOI: 10.1017/ice.2021.227.Peer-Reviewed Original Research
2020
Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2
Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Warren JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, Ko AI. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. New England Journal Of Medicine 2020, 383: 1283-1286. PMID: 32857487, PMCID: PMC7484747, DOI: 10.1056/nejmc2016359.Peer-Reviewed Original Research
2019
Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures
Datta R, Wang T, Zhu M, Dembry LM, Han L, Allore H, Quagliarello V, Juthani-Mehta M. Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures. Infection Control And Hospital Epidemiology 2019, 40: 470-472. PMID: 30821230, PMCID: PMC6482377, DOI: 10.1017/ice.2019.22.Peer-Reviewed Original ResearchConceptsUrinary tract infectionIncidence rate ratiosAdvanced cancer patientsAsymptomatic bacteriuriaCancer patientsAntimicrobial therapySymptomatic urinary tract infectionPotential urinary tract infectionTract infectionsInappropriate therapyAntimicrobial daysComfort measuresBacteriuriaCandiduriaCFU/mLPatientsTherapyRate ratioMLInfection
2018
Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report
Datta R, Advani S, Rink A, Bianco L, Van Ness PH, Quagliarello V, Juthani-Mehta M. Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report. Open Access Journal Of Gerontology & Geriatric Medicine 2018, 4: 555636. PMID: 30465048, PMCID: PMC6241532, DOI: 10.19080/oajggm.2018.04.555636.Peer-Reviewed Original ResearchLong-term care residentsUrinary tract infectionUrine isolatesCare residentsTract infectionsUncomplicated urinary tract infectionsLong-term care facilitiesTrimethoprim/sulfamethoxazoleEmpiric therapyCommon indicationOptimal therapyUrine cultureUrinary isolatesAntimicrobial therapyClinical trialsNitrofurantoin susceptibilityCare facilitiesFluoroquinolone susceptibilityAntimicrobial susceptibilityPredominant organismTherapyInfectionCefazolinIsolatesBacterial isolatesFrequency of Infection during Fever Episodes among Long-Term Care Residents
Datta R, Advani S, Rink A, Bianco L, Van Ness PH, Quagliarello V, Juthani-Mehta M. Frequency of Infection during Fever Episodes among Long-Term Care Residents. Journal Of Gerontology & Geriatric Research 2018, 7: 1-2. PMID: 30197840, PMCID: PMC6128293, DOI: 10.4172/2167-7182.1000467.Peer-Reviewed Original ResearchLong-term care residentsLong-term care facilitiesFever episodesFrequency of infectionCare residentsCare facilitiesCase series analysisAdverse event surveillanceOlder adult womenCranberry capsulesMedian ageRandomized trialsSurveillance definitionsProvider assessmentTotal infectionsAdult womenInfectionOlder adultsEvent surveillanceWomenEpisodesTwo-thirdsResidentsPyuriaBacteriuria
2017
Burden and Management of Multidrug-Resistant Organisms in Palliative Care
Datta R, Juthani-Mehta M. Burden and Management of Multidrug-Resistant Organisms in Palliative Care. Palliative Care And Social Practice 2017, 10: 1178224217749233. PMID: 29317826, PMCID: PMC5753884, DOI: 10.1177/1178224217749233.Peer-Reviewed Original ResearchMultidrug-resistant organismsPalliative careTerminal illnessGoals of palliationPalliative care patientsPalliative care settingAvailable treatment optionsInfection prevention measuresQuality of lifeCommon complicationContact precautionsMetastatic diseaseCare patientsPatient isolationTreatment optionsSymptom assessmentCare discussionsAntimicrobial therapyCommon signsCare settingsCognitive impairmentPsychological burdenPatientsInfectionAdverse effects
2013
High Nasal Burden of Methicillin-Resistant Staphylococcus aureus Increases Risk of Invasive Disease
Datta R, Shah A, Huang SS, Cui E, Nguyen V, Welbourne SJ, Quan KA, Thrupp L. High Nasal Burden of Methicillin-Resistant Staphylococcus aureus Increases Risk of Invasive Disease. Journal Of Clinical Microbiology 2013, 52: 312-314. PMID: 24153126, PMCID: PMC3911445, DOI: 10.1128/jcm.01606-13.Peer-Reviewed Original Research
2010
Risk of Postdischarge Infection with Vancomycin-Resistant Enterococcus after Initial Infection or Colonization
Datta R, Huang SS. Risk of Postdischarge Infection with Vancomycin-Resistant Enterococcus after Initial Infection or Colonization. Infection Control And Hospital Epidemiology 2010, 31: 1290-1293. PMID: 20979493, PMCID: PMC3075426, DOI: 10.1086/657332.Peer-Reviewed Original ResearchAnimal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice
Skurnik D, Merighi M, Grout M, Gadjeva M, Maira-Litran T, Ericsson M, Goldmann DA, Huang SS, Datta R, Lee JC, Pier GB. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. Journal Of Clinical Investigation 2010, 120: 3220-3233. PMID: 20739753, PMCID: PMC2929724, DOI: 10.1172/jci42748.Peer-Reviewed Original ResearchConceptsS. aureus infectionPoly-N-acetyl glucosamineAureus infectionOpsonic killingCapsular polysaccharideNew prophylactic approachS. aureus bacteremiaCommunity-acquired infectionsStaphylococcus aureus antigenOPK activityAureus bacteremiaProtective immunityComplement depositionEffective immunityProphylactic approachMouse modelSuch antigensVaccine componentsIdiotype interactionsHuman immunityAnimal antiseraGram-positive bacterial pathogensHuman antibodiesInfectionMonoclonal antibodies
2008
Risk of Infection and Death due to Methicillin- Resistant Staphylococcus aureus in Long-Term Carriers
Datta R, Huang SS. Risk of Infection and Death due to Methicillin- Resistant Staphylococcus aureus in Long-Term Carriers. Clinical Infectious Diseases 2008, 47: 176-181. PMID: 18532892, PMCID: PMC2649874, DOI: 10.1086/589241.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBacteremiaBostonCarrier StateCatheterization, Central VenousCohort StudiesFemaleHospitalizationHumansLogistic ModelsMaleMethicillin ResistanceMiddle AgedPneumoniaRetrospective StudiesRisk FactorsSex FactorsSoft Tissue InfectionsStaphylococcal InfectionsStaphylococcus aureusTime FactorsConceptsMethicillin-resistant Staphylococcus aureusLong-term carriersRisk of infectionMRSA infectionSingle-center retrospective cohort studyCentral venous catheter infectionSubsequent MRSA infectionVenous catheter infectionRetrospective cohort studyShort-term morbiditySoft tissue infectionsDuration of carriageStaphylococcus aureusMRSA colonizationCohort studyCatheter infectionCommon infectionsNew hospitalizationHigh riskSubsequent infectionTime of detectionPersistent riskInfectionSignificant riskDeathStrain-Relatedness of Methicillin- Resistant Staphylococcus aureus Isolates Recovered from Patients with Repeated Infection
Huang SS, Diekema DJ, Warren DK, Zuccotti G, Winokur PL, Tendolkar S, Boyken L, Datta R, Jones RM, Ward MA, Aubrey T, Onderdonk AB, Garcia C, Platt R. Strain-Relatedness of Methicillin- Resistant Staphylococcus aureus Isolates Recovered from Patients with Repeated Infection. Clinical Infectious Diseases 2008, 46: 1241-1247. PMID: 18444862, PMCID: PMC2723744, DOI: 10.1086/529381.Peer-Reviewed Original ResearchConceptsMethicillin-Resistant Staphylococcus aureus IsolatesMethicillin-resistant Staphylococcus aureus (MRSA) detectionStaphylococcus aureus isolatesMRSA infectionRepeated infectionsInvasive diseaseLate infectionAureus isolatesInfectionSame strainInitial detectionMost casesStaphylococcus aureus detectionIsolatesPatientsDiseaseWeeks